[胃癌同步肝转移的多模态治疗评估]
[Evaluation of multimodality therapy for synchronous liver metastases of gastric cancer].
作者信息
Sasaki Hiroshi, Ninomiya Motoki, Yano Shuya, Umeoka Tatsuo, Harano Masao, Aoki Hideki, Onoda Tadashi, Shiozaki Shigehiro, Ohno Satoshi, Higaki Kenji, Takakura Norihisa
机构信息
Dept. of Surgery, Hiroshima City Hospital.
出版信息
Gan To Kagaku Ryoho. 2004 Oct;31(11):1924-6.
We evaluated the significance of multimodality therapy for cases of liver metastases of gastric cancer. Accumulated survival rate and median survival time were analyzed for twenty cases of such gastric cancer. Survival rates of H1+H2 group and hepatic resection (HR) group were higher than that of H3 group and non-HR group. MST of HR group and hepatic arterial infusion (HAI) group were longer than that of non-HR group and non-HAI group. Survival rate of HAI group was higher than that of non-HAI group among eleven cases of HR group. On the other hand, survival rate of HR group was higher than that of non-HR group among eleven cases of HAI group. These results suggested that HAI chemotherapy after hepatic resection for gastric cancer patients with synchronous liver metastasis would improve prognosis.
我们评估了多模式治疗对胃癌肝转移病例的意义。分析了20例此类胃癌患者的累积生存率和中位生存时间。H1+H2组和肝切除（HR）组的生存率高于H3组和非HR组。HR组和肝动脉灌注（HAI）组的中位生存时间长于非HR组和非HAI组。在HR组的11例患者中，HAI组的生存率高于非HAI组。另一方面，在HAI组的11例患者中，HR组的生存率高于非HR组。这些结果表明，对于同步肝转移的胃癌患者，肝切除术后进行HAI化疗可改善预后。
Zotero 插件